Business Wire·Mar 25, 2026, 8:00 AM ET

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

BIAF BIAFW

bioAffinity Technologies, Inc. will host the first "CyPath® Lung in Practice" webinar on April 8, 2026, featuring a panel of pulmonologists discussing real-world clinical cases.
The April 8, 2026, live Zoom session will occur at 7 p.m. ET/6 p.m. CT, with registration available via a provided link.
Panelists include Gordon H. Downie, MD, PhD, who will moderate, along with Dr. Sai Karan Vamsi Guda, Dr. Michael Nicholson, and Dr. Gregory White.
The discussion will focus on using CyPath® Lung for diagnosing indeterminate pulmonary nodules, managing lung cancer risk, & surveilling lung cancer survivors post-treatment.
Physicians will share case studies demonstrating the test's ability to detect Stage 1A lung cancer & prevent unnecessary invasive procedures when malignancy is deemed "Unlikely."
CyPath® Lung is a noninvasive Laboratory Developed Test (LDT) that uses flow cytometry, AI, & fluorescent porphyrins to analyze patient sputum for malignancy indicators.
Clinical study results for CyPath® Lung show 92% sensitivity, 87% specificity, & 88% accuracy in detecting lung cancer in patients with small indeterminate nodules under 20 millimeters.
The webinar will be recorded & posted on the CyPath® Lung website for later viewing.
bioAffinity Technologies markets CyPath® Lung through Precision Pathology Laboratory Services, which operates under CLIA regulations administered by CMS.
The press release includes standard forward-looking statement disclaimers regarding commercialization, regulatory approvals, & adoption risks.